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goodness-of-fit of the final model. Optimism-corrected 
survival proportions were calculated. All analyses were 
performed according to the TRIPOD statement. 
 
Results: 28 (45%) patients died from PCa after mean (±SD) 82 
(±36) months. Median total follow-up was 78 months (range 
5-139). In total, 36 patients (58%) patients died after mean 
84 (±40) months. PSA doubling time (PSADT) remained as a 
predictive factor for both PCaSM and OM: corrected hazard 
ratio’s (HR’s) 0.92 (95%-CI: 0.86-0.98, p=0.02) and 0.94 (95%-
CI: 0.90-0.99, p=0.01), respectively. The adjusted C-statistics 
were 0.71 and 0.69, respectively. Predictive ability 
(calibration) was good up to 96 months follow-up. Over 80% 
of patients can survive 8 years if PSADT>24 months (PCaSM) 
and >33 months (OM) (Figure 1).  
 
Figure 1: Prostate cancer specific survival (PCaSS) and overall 
survival (OS) as a function of PSADT. 
 
Conclusion: A PSADT >24 months and >33 months can result 
in a high probability (>80%) of prostate cancer specific and 
overall survival 8 years after TS I-125 BT. Larger series and 
external validation are necessary. 
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Purpose or Objective: Locally recurrent prostate cancer 
reirradiation may lead to urethral stricture and increase of 
urinary symptoms including urinary retention. Such patients 
may undergo urethretomy or transurethral resection of the 
prostate (TURP), which may cause urinary incontinence. Our 
purpose was to evaluate risk of urinary incontinence after 
salvage high-dose-rate brachytherapy (HDR BT) with or 
without urological intervention.  
 
Material and Methods: We included in the analysis all salvage 
HDR BT patients with at least 6 months of follow-up. Urinary 
retention, urological interventions and urinary incontinence 
rates were assessed. 5-year adverse event-free survivals were 
calculated.  
 
Results: One hundred and two men were enrolled in this 
retrospective analysis. Median age was 71 years (57-81). 
Median follow-up was 37 months (6-76). Twenty-three men 
(23%) underwent urological intervention after salvage HDR 
BT. Fourteen of them suffered from urinary retention, 9 men 
were treated due to refractory obstructive urinary symptoms. 
TURP or urethretomy was performed 15 and 12 times, 
respectively. Four patients underwent combination of both. 
Twelve patients suffered from urinary incontinence with no 
intervention, twenty men developed it after urological 
intervention. Five patients needed suprapubic catheter. 5-
year urological intervention-free survival was 65%. 5-year 
urinary incontinence-free survival (UIFS) was 69%. Any 
urological intervention was linked with higher urinary 
incontinence probability (4-year UIFS 88% vs 5%, p-0.0000; 
HR-14.05; 95% CI 13.25-14.85).  
 
Conclusion: There is high probability of urinary incontinence 
in salvage HDR BT prostate cancer patients after urological 
intervention (TURP/urethrotomy). Therefore patients 
suffering from refractory obstructive urinary symptoms 
without urinary retention should be carefully evaluated and 
counseled before any urological management. 
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Purpose or Objective: To evaluate the technical feasibility 
and safety of focal MRI guided HDR brachytherapy as a 
primary, salvage or secondary salvage treatment in 37 
patient with a localized (recurrent) prostate cancer. 
 
Material and Methods: From May 2013 until October 2015, 37 
patients were treated with focal MRI guided HDR 
brachytherapy. 26 patients received MRI guided primary focal 
HDR brachytherapy, 8 patients salvage treatment and 3 
patient secondary salvage treatment. The prescribed dose to 
the PTV was 19 Gy, with strict limitations to the organs at 
risk. Patients with a (recurrent) PA proven prostate cancer 
were included in this evaluation. Before treatment, a 
diagnostic multiparametric MR was performed to define the 
tumor region. In patients with recurrent disease, a choline 
PET scan or PSMA scan was performed to exclude patients 
with early distant metastasis. The treatment was performed 
through MR guidance, in a combined MR/HDR facility (Figure 
1).  
 
 
 
After ultrasound guided insertion of the catheters, an MRI of 
the prostate was performed for the reconstruction of the 
inserted catheters. Consequently, a per-operative treatment 
plan was performed prior to dose delivery. Toxicity was 
measured using the CTCAE version 4. 
 
